Omadacycline + Moxifloxacin
Phase 3Recruiting 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Community-acquired Bacterial Pneumonia
Conditions
Community-acquired Bacterial Pneumonia
Trial Timeline
Nov 17, 2023 → Nov 30, 2025
NCT ID
NCT06162286About Omadacycline + Moxifloxacin
Omadacycline + Moxifloxacin is a phase 3 stage product being developed by Zai Lab for Community-acquired Bacterial Pneumonia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06162286. Target conditions include Community-acquired Bacterial Pneumonia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06162286 | Phase 3 | Recruiting |
Competing Products
9 competing products in Community-acquired Bacterial Pneumonia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ONO-5046Na + ONO-5046Na | Ono Pharmaceutical | Phase 2 | 52 |
| Ceftaroline + Ceftriaxone | Pfizer | Phase 3 | 76 |
| Azithromycin microspheres 2.0 single dose | Pfizer | Phase 3 | 76 |
| IV azithromycin + ceftriaxone + oral azithromycin + IV levofloxacin + oral levofloxacin | Pfizer | Approved | 84 |
| Azithromycin SR | Pfizer | Phase 3 | 76 |
| Azithromycin SR + Amoxiclav | Pfizer | Pre-clinical | 22 |
| tigecycline | Pfizer | Phase 3 | 76 |
| Tigecycline + Levofloxacin | Pfizer | Phase 3 | 76 |
| ceftobiprole medocaril + IV standard-of-care cephalosporin | Basilea Pharmaceutica | Phase 3 | 72 |